Lupin Limited , a global pharmaceutical leader, has achieved a significant milestone in its manufacturing capabilities. The company announced that its Active Pharmaceutical Ingredient (API) facility in Dabhasa, Gujarat, has received Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration (TGA) of Australia.

Key Highlights

• Lupin's wholly-owned subsidiary, Lupin Manufacturing Solutions Limited (LMS), operates the Dabhasa API facility.
• The TGA, Australia's medicines and medical devices regulator, granted the GMP certification after a thorough inspection.
• This certification underscores Lupin's commitment to maintaining high-quality manufacturing standards across its facilities.

Strategic Importance

The GMP certification from TGA Australia for the Dabhasa API facility is a testament to Lupin's dedication to quality and compliance in pharmaceutical manufacturing. This achievement is expected to strengthen Lupin's position in the global pharmaceutical market, particularly in Australia and other regions that recognize TGA certifications.

Dr. Abdelaziz Toumi, Chief Executive Officer of Lupin Manufacturing Solutions, expressed his satisfaction with the certification, stating, "We are pleased to have received the GMP certification from TGA for our Dabhasa facility. This reflects the high standard of our manufacturing practices and expertise of our team at Dabhasa."

Expanding Global Footprint

The certification aligns with Lupin's strategy to expand its global presence. Dr. Toumi emphasized the company's focus on quality, compliance, and operational integrity, adding, "As we continue to expand our global footprint, we remain focused on quality, compliance, and the highest standards of operational integrity, setting new benchmarks in the CDMO space."

About Lupin Manufacturing Solutions

Lupin Manufacturing Solutions (LMS) is a wholly-owned subsidiary of Lupin Limited, specializing in manufacturing and supplying high-quality, cost-effective Active Pharmaceutical Ingredients (APIs). LMS positions itself as the "Partner of Choice" in the Contract Development and Manufacturing Operations (CDMO) space for drug substances.

Lupin's Global Presence

Lupin Limited, headquartered in Mumbai, India, has a strong presence in over 100 markets worldwide. The company is known for its pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and APIs. With 15 state-of-the-art manufacturing sites and 7 research centers globally, Lupin employs over 23,000 professionals dedicated to improving patient health outcomes.

This latest certification for the Dabhasa API facility reinforces Lupin's reputation as a quality-focused pharmaceutical manufacturer and is expected to contribute to its ongoing growth and expansion in the global pharmaceutical market.

Lupin Limited , a global pharmaceutical leader, has recently undergone a U.S. Food and Drug Administration (FDA) inspection at its Pithampur Unit-2 manufacturing facility, resulting in four observations. The company has affirmed its commitment to addressing these concerns promptly and ensuring full compliance with FDA requirements.

Inspection Details

According to a disclosure made by Lupin Limited to the National Stock Exchange of India and BSE Limited, the FDA inspection of the Pithampur Unit-2 manufacturing facility took place from July 8 to July 17. The inspection concluded with the issuance of a Form-483, which contained four observations.

Company's Response

Lupin has stated that it is addressing these observations comprehensively and will respond to the U.S. FDA within the stipulated timeframe. In their official statement, the company emphasized, "We uphold quality and compliance with utmost importance and are committed to be compliant with CGMP quality standards across all our facilities."

Implications and Commitment to Quality

The issuance of FDA observations is a significant event for pharmaceutical companies, as it can potentially impact their ability to manufacture and distribute products in the U.S. market. Lupin's prompt acknowledgment of the situation and commitment to resolving the issues demonstrate the company's proactive approach to maintaining high-quality standards.

Other Recent Developments

It's worth noting that Lupin has also faced similar scrutiny at other facilities. The company disclosed that its Pithampur Unit-3 manufacturing facility was inspected by the U.S. FDA from July 7 to July 17, resulting in three observations.

On a positive note, Lupin Manufacturing Solutions Limited, a wholly owned subsidiary of Lupin, recently received Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration (TGA), Australia's medicines and medical devices regulator, for its API manufacturing facility in Dabhasa, Gujarat.

Looking Ahead

As Lupin works to address the FDA observations at its Pithampur Unit-2 facility, investors and industry observers will be closely monitoring the company's progress in resolving these issues and maintaining its regulatory compliance across all its manufacturing units.

The pharmaceutical giant's ability to swiftly and effectively address these regulatory challenges will be crucial in maintaining its strong position in the global pharmaceutical market, particularly in key markets like India and the United States.